-
公开(公告)号:US20120237496A1
公开(公告)日:2012-09-20
申请号:US13378764
申请日:2010-06-21
申请人: Joerg Birkenfeld , Andrea Eicker , Per-Ola Freskgard , Claudia Gotzberger-Schad , Joanna Grudzinska , Ulrich Haupts , Josi Innig , Christoph Mahlert , Andreas Scheidig , Michael Strerath , Jan Tebbe , Johan Per-Wallin , Nina Wobst , Carl Innes Webster , Lutz Jermutus
发明人: Joerg Birkenfeld , Andrea Eicker , Per-Ola Freskgard , Claudia Gotzberger-Schad , Joanna Grudzinska , Ulrich Haupts , Josi Innig , Christoph Mahlert , Andreas Scheidig , Michael Strerath , Jan Tebbe , Johan Per-Wallin , Nina Wobst , Carl Innes Webster , Lutz Jermutus
IPC分类号: A61K38/48 , C12N9/96 , C12N5/10 , A61P25/28 , C12N1/19 , C12N15/63 , C12N15/57 , C12N9/64 , C12N1/15
CPC分类号: C12N9/6494 , A61K38/00 , C12Y304/24011
摘要: The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta.
摘要翻译: 本发明涉及包含具有改变的特异性和/或活性的野生型人体炎蛋白的蛋白酶变体的多肽。 特别地,本发明涉及包含衍生自人尼泊金的蛋白酶变体的多肽,其具有针对某些底物,特别是针对淀粉样β的特异性和/或活性增加。
-
公开(公告)号:US20130122024A1
公开(公告)日:2013-05-16
申请号:US13451916
申请日:2012-04-20
申请人: Hans-Georg LERCHEN , Beatrix STELTE-LUDWIG , Sven GOLFIER , Charlotte Christine KOPITZ , Rudolf BEIER , Sherif EL SHEIKH , Iring HEISLER , Axel HARRENGA , Karl-Heinz THIERAUCH , Joachim SCHUHMACHER , Sandra BRUDER , Simone GREVEN , Lars LINDEN , Jörg WILLUDA , Christoph MAHLERT , Heike PETRUL , Hannah JÖRIßEN , Sandra Borkowski
发明人: Hans-Georg LERCHEN , Beatrix STELTE-LUDWIG , Sven GOLFIER , Charlotte Christine KOPITZ , Rudolf BEIER , Sherif EL SHEIKH , Iring HEISLER , Axel HARRENGA , Karl-Heinz THIERAUCH , Joachim SCHUHMACHER , Sandra BRUDER , Simone GREVEN , Lars LINDEN , Jörg WILLUDA , Christoph MAHLERT , Heike PETRUL , Hannah JÖRIßEN , Sandra Borkowski
IPC分类号: C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06
CPC分类号: A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , C07K5/0205 , C07K5/0207 , C07K5/06 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target mesothelin, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
摘要翻译: 本申请涉及针对靶间皮素的N,N-二烷基海马素的新粘合剂 - 药物偶联物(ADC),这些ADC的活性代谢物,制备这些ADC的方法,以及使用这些ADC用于治疗和 /或预防疾病,以及使用这些ADC用于制备用于治疗和/或预防疾病的药物,更特别是过度增殖和/或血管生成疾病,例如癌症疾病。 这样的治疗可以作为单一疗法来实施,或者与其它药物组合或进一步的治疗措施。
-
公开(公告)号:US20140127240A1
公开(公告)日:2014-05-08
申请号:US14113070
申请日:2012-04-20
申请人: Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte C. Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Brokowski
发明人: Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte C. Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Brokowski
CPC分类号: A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , C07K5/0205 , C07K5/0207 , C07K5/06 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要: The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.
摘要翻译: 本专利申请涉及针对靶表皮生长因子受体(EGFR,基因ID 1956)的N,N-二烷基硫酸锡的新型粘合剂 - 药物共轭物(ADC),这些ADC的有效代谢物,制备这些ADC的方法, 这些ADC用于治疗和/或预防疾病,以及使用这些ADC来制备用于治疗和/或预防疾病,特别是过度增生和/或血管发生疾病例如癌症的药物。 这样的治疗可以作为单一疗法或与其它药物或其他治疗措施组合施用。
-
公开(公告)号:US20130066055A1
公开(公告)日:2013-03-14
申请号:US13451950
申请日:2012-04-20
申请人: Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte Christine Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörissen , Sandra Borkowski
发明人: Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Jörg Willuda , Charlotte Christine Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörissen , Sandra Borkowski
IPC分类号: C07K17/02
CPC分类号: A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , C07K5/0205 , C07K5/0207 , C07K5/06 , C07K5/06034 , C07K5/06052 , C07K5/0606 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/28 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
摘要翻译: 本申请涉及针对目标C4.4a的N,N-二烷基硫酸钠的新粘合剂 - 药物共轭物(ADC),这些ADC的活性代谢物,制备这些ADC的方法,使用这些ADC 治疗和/或预防疾病,以及使用这些ADC用于制备用于治疗和/或预防疾病的药物,更特别是过度增殖和/或血管生成疾病,例如癌症疾病。 这样的治疗可以作为单一疗法来实施,或者与其它药物组合或进一步的治疗措施。
-
-
-